Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Thrombotic risk with thrombopoietin receptor agonists in immune thrombocytopenia: Real-world evidence from a multicenter Japanese study.

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHiroto HoriguchiTKTakeshi KondoYKYasutaka Kakinoki

Discussion

Loading...

Member takes

Overview

Real-world evidence shows thrombotic events linked to treatment responses and risk factors in ITP patients, implying monitoring needs.

Key Points

  • This study aims to identify thrombotic risk factors in patients with immune thrombocytopenia in Japan.
  • Retrospective analysis of 687 ITP patients diagnosed between 2011 and 2020.
  • Data collected included thrombosis history, cardiovascular risk factors, and treatment responses.
  • Multivariate Cox regression analysis was utilized to identify risk factors.
  • Thrombotic events occurred in 31 patients (4.5%).
  • Thrombotic risk increased significantly in TPO-RA-treated patients with aPL positivity and prior thrombosis.
  • Cumulative thrombosis incidence was higher among patients with a thrombotic history (p=0.00081).

Cite This Study

Horiguchi et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d912https://doi.org/10.1182/blood-2025-1259
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1No significant increase in thrombotic risk following the widespread adoption of TPO-RAs in ITP: A comparative study2026
  2. 2Beyond Platelet Counts: Assessing Safety of Post-Splenectomy TPO-RA Use in ITP2025
  3. 3Efficacy and Thrombotic Risk of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia Secondary to Systemic Lupus and Antiphospholipid Syndrome: French Experience With 80 Patients2025 · 5 citations
  4. 4Thromboembolic adverse events associated with TPO-RA in ITP treatment: a pharmacovigilance analysis of the FDA Adverse Event Reporting System2026
  5. 5Bridging the gaps between randomized controlled trials and real-world use of thrombopoietin receptor agonists for adult primary immune thrombocytopenia: a systematic review and meta-analysis2025